Incyte Receives EC Approval for Povofortay Skin Disease Treatment
Key Facts
Incyte secured European Commission approval for Povofortay as the first once-daily oral treatment for hidradenitis suppurativa in the European Union. Zacks reported that this approval marks a significant regulatory milestone for the company's dermatology portfolio. The decision was based on clinical results, providing a new therapeutic option for patients with this chronic skin condition.
Incyte shares closed at $120.27 on November 16, 2026, prior to the commission's announcement. The stock traded between a low of $119.79 and a high of $122.94 during that session. This expansion into the European market serves as a positive growth driver for the company given the limited treatment options currently available for the condition.